These Analysts Increase Their Forecasts On PTC Therapeutics

Benzinga

29 Jul

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced it has gained FDA approval for SEPHIENCE on Monday.

“We are excited to have reached this important milestone for those affected by PKU,” said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. “The broad labeling reflects the potential of Sephience to meet the significant unmet need of PKU patients. The Sephience clinical data along with our expertise in launching rare disease therapies position Sephience to become the future standard of care. Our experienced customer facing teams are ready to bring this therapy to children and adults with PKU in the United States as quickly as possible.”

PTC Therapeutics shares gained 11.7% to trade at $49.53 on Tuesday.

These analysts made changes to their price targets on PTC Therapeutics following the announcement.

UBS analyst Colin Bristow maintained PTC Therapeutics with a Buy and raised the price target from $71 to $80.
Cantor Fitzgerald analyst Kristen Kluska maintained PTC Therapeutics with an Overweight rating and raised the price target from $112 to $120.
Wells Fargo analyst Tiago Fauth maintained the stock with an Overweight rating and raised the price target from $74 to $78.
Barclays analyst Gena Wang maintained PTC Therapeutics with an Equal-Weight rating and raised the price target from $42 to $46.

Considering buying PTCT stock? Here’s what analysts think:

Read This Next:

Boeing, Procter & Gamble And 3 Stocks To Watch Heading Into Tuesday

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2555050628"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555050628\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2555050628?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 23:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555050628","market":"hk","top_or_hot":-1,"title":"These Analysts Increase Their Forecasts On PTC Therapeutics","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/PTCT\">PTC Therapeutics</a>, Inc.</strong> (NASDAQ:PTCT) announced it has gained FDA approval for SEPHIENCE on Monday.</p>\n<p>“We are excited to have reached this important milestone for those affected by PKU,” said Matthew B. Klein, M.D., Chief Executive Officer of PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. “The broad labeling reflects the potential of Sephience to meet the significant unmet need of PKU patients. The Sephience clinical data along with our expertise in launching rare disease therapies position Sephience to become the future standard of care. Our experienced customer facing teams are ready to bring this therapy to children and adults with PKU in the <a href=\"https://laohu8.com/S/UBCP\">United</a> States as quickly as possible.”</p>\n<p>PTC Therapeutics shares gained 11.7% to trade at $49.53 on Tuesday.</p>\n<p>These analysts made changes to their price targets on PTC Therapeutics following the announcement.</p>\n<ul>\n<li>UBS analyst Colin Bristow maintained PTC Therapeutics with a Buy and raised the price target from $71 to $80.</li>\n<li>Cantor Fitzgerald analyst Kristen Kluska maintained PTC Therapeutics with an Overweight rating and raised the price target from $112 to $120.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Tiago Fauth maintained the stock with an Overweight rating and raised the price target from $74 to $78.</li>\n<li>Barclays analyst Gena Wang maintained PTC Therapeutics with an Equal-Weight rating and raised the price target from $42 to $46.</li>\n</ul>\n<p><strong>Considering buying PTCT stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"586\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458-1024x586.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458.png 1100w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong><a href=\"https://laohu8.com/S/BA\">Boeing</a>, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Tuesday</strong></li>\n</ul>\n<p>Photo via <a href=\"https://laohu8.com/S/SSTK\">Shutterstock</a></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Increase Their Forecasts On PTC Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Increase Their Forecasts On PTC Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-07-29 23:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/PTCT\">PTC Therapeutics</a>, Inc.</strong> (NASDAQ:PTCT) announced it has gained FDA approval for SEPHIENCE on Monday.</p>\n<p>“We are excited to have reached this important milestone for those affected by PKU,” said Matthew B. Klein, M.D., Chief Executive Officer of PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. “The broad labeling reflects the potential of Sephience to meet the significant unmet need of PKU patients. The Sephience clinical data along with our expertise in launching rare disease therapies position Sephience to become the future standard of care. Our experienced customer facing teams are ready to bring this therapy to children and adults with PKU in the <a href=\"https://laohu8.com/S/UBCP\">United</a> States as quickly as possible.”</p>\n<p>PTC Therapeutics shares gained 11.7% to trade at $49.53 on Tuesday.</p>\n<p>These analysts made changes to their price targets on PTC Therapeutics following the announcement.</p>\n<ul>\n<li>UBS analyst Colin Bristow maintained PTC Therapeutics with a Buy and raised the price target from $71 to $80.</li>\n<li>Cantor Fitzgerald analyst Kristen Kluska maintained PTC Therapeutics with an Overweight rating and raised the price target from $112 to $120.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Tiago Fauth maintained the stock with an Overweight rating and raised the price target from $74 to $78.</li>\n<li>Barclays analyst Gena Wang maintained PTC Therapeutics with an Equal-Weight rating and raised the price target from $42 to $46.</li>\n</ul>\n<p><strong>Considering buying PTCT stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"586\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458-1024x586.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458.png 1100w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong><a href=\"https://laohu8.com/S/BA\">Boeing</a>, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Tuesday</strong></li>\n</ul>\n<p>Photo via <a href=\"https://laohu8.com/S/SSTK\">Shutterstock</a></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1951198990.SGD","symbol_name":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46694312/these-analysts-increase-their-forecasts-on-ptc-therapeutics","article_id":"2555050628","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555050628","pubTimestamp":1753802601,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2506952337.HKD":"BNP PARIBAS CLIMATE IMPACT \"CRH\" (HKDHDG) ACC","LU1721428347.USD":"BNP PARIBAS CLIMATE IMPACT \"C\" (USD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU2477742899.HKD":"BNP PARIBAS CLIMATE IMPACT \"C\" (HKD) ACC","LU2506952410.USD":"BNP PARIBAS CLIMATE IMPACT \"CRH\" (USDHDG) ACC A","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","PTCT":"PTC Therapeutics Inc.","BK4023":"应用软件","BK4554":"元宇宙及AR概念","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4576":"AR","BK4139":"生物科技","PTC":"PTC Inc."},"translate_title":"这些分析师上调了对PTC Therapeutics的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTC":1,"PTCT":1},"content_text":"PTC Therapeutics, Inc. (NASDAQ:PTCT) announced it has gained FDA approval for SEPHIENCE on Monday.\n“We are excited to have reached this important milestone for those affected by PKU,” said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. “The broad labeling reflects the potential of Sephience to meet the significant unmet need of PKU patients. The Sephience clinical data along with our expertise in launching rare disease therapies position Sephience to become the future standard of care. Our experienced customer facing teams are ready to bring this therapy to children and adults with PKU in the United States as quickly as possible.”\nPTC Therapeutics shares gained 11.7% to trade at $49.53 on Tuesday.\nThese analysts made changes to their price targets on PTC Therapeutics following the announcement.\n\nUBS analyst Colin Bristow maintained PTC Therapeutics with a Buy and raised the price target from $71 to $80.\nCantor Fitzgerald analyst Kristen Kluska maintained PTC Therapeutics with an Overweight rating and raised the price target from $112 to $120.\nWells Fargo analyst Tiago Fauth maintained the stock with an Overweight rating and raised the price target from $74 to $78.\nBarclays analyst Gena Wang maintained PTC Therapeutics with an Equal-Weight rating and raised the price target from $42 to $46.\n\nConsidering buying PTCT stock? Here’s what analysts think: \n\nRead This Next: \n\nBoeing, Procter & Gamble And 3 Stocks To Watch Heading Into Tuesday\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}